BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28265335)

  • 1. Inappropriate Off-label Use of a Qualitative, Point-of-care hCG Device.
    Nerenz RD; Gronowski AM; Grenache DG
    West J Emerg Med; 2017 Feb; 18(2):324-325. PubMed ID: 28265335
    [No Abstract]   [Full Text] [Related]  

  • 2. In reply to: “Inappropriate Off-label Use of a Qualitative, Point-of-care hCG Device”.
    Gottlieb M; Wnek K; Moskoff J; Christian E; Bailitz J
    West J Emerg Med; 2017 Feb; 18(2):326. PubMed ID: 29911828
    [No Abstract]   [Full Text] [Related]  

  • 3. Using a simulation model to assess risk of false negative point-of-care urinary human chorionic gonadotropin device results due to high-dose hook interference.
    Milhorn D; Korpi-Steiner N
    Clin Biochem; 2015 Feb; 48(3):99-104. PubMed ID: 25448030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point-of-care and over-the-counter qualitative human chorionic gonadotropin (hCG) devices remain susceptible to false-negative results caused by excess hCG β core fragment.
    Nerenz RD; Gronowski AM
    Clin Chem; 2013 Nov; 59(11):1672-4. PubMed ID: 23985957
    [No Abstract]   [Full Text] [Related]  

  • 5. Performance of qualitative urinary hCG assays.
    Nickmans S; Vermeersch P; Van Eldere J; Billen J
    Acta Clin Belg; 2014 Aug; 69(4):277-9. PubMed ID: 24846178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. False-negative results in point-of-care qualitative human chorionic gonadotropin (hCG) devices due to excess hCGbeta core fragment.
    Gronowski AM; Cervinski M; Stenman UH; Woodworth A; Ashby L; Scott MG
    Clin Chem; 2009 Jul; 55(7):1389-94. PubMed ID: 19395437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening method to evaluate point-of-care human chorionic gonadotropin (hCG) devices for susceptibility to the hook effect by hCG β core fragment: evaluation of 11 devices.
    Nerenz RD; Song H; Gronowski AM
    Clin Chem; 2014 Apr; 60(4):667-74. PubMed ID: 24463559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the CLINITEST® human chorionic gonadotropin (hCG) pregnancy test for susceptibility to the hook effect by the hCG β core fragment.
    Ledden DJ; Novamo AK; Schulman LS
    Clin Chem; 2014 Dec; 60(12):1578-80. PubMed ID: 25248572
    [No Abstract]   [Full Text] [Related]  

  • 9. Heterophile antibody interference in qualitative urine/serum hCG devices: Case report.
    Patel KK; Gronowski AM
    Clin Biochem; 2016 Jun; 49(9):729-731. PubMed ID: 26968106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gelofusine affects the quality control performance of QuickVue point-of-care human chorionic gonadotropin test devices.
    de Boer D; Houben C; Bekers O; Menheere PP
    Clin Biochem; 2010 Nov; 43(16-17):1371-2. PubMed ID: 20727868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. False-Negative Urine Human Chorionic Gonadotropin Testing in the Clinical Laboratory.
    Herskovits AZ; Chen Y; Latifi N; Ta RM; Kriegel G
    Lab Med; 2020 Jan; 51(1):86-93. PubMed ID: 31245816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ambulatory human chorionic gonadotrophin (hCG) testing: a verification of two hCG point of care devices.
    Kyriacou C; Yang W; Kapur S; Maheetharan S; Pikovsky M; Parker N; Barcroft J; Bobdiwala S; Sur S; Stalder C; Gould D; Ofili-Yebovi D; Day A; Unsworth N; Wilkes EH; Tan T; Bourne T
    Clin Chem Lab Med; 2024 Mar; 62(4):664-673. PubMed ID: 37886834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hCG assay or pregnancy test.
    Cole LA
    Clin Chem Lab Med; 2012 Apr; 50(4):617-30. PubMed ID: 22149742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qualitative point-of-care and over-the-counter urine hCG devices differentially detect the hCG variants of early pregnancy.
    Cervinski MA; Lockwood CM; Ferguson AM; Odem RR; Stenman UH; Alfthan H; Grenache DG; Gronowski AM
    Clin Chim Acta; 2009 Aug; 406(1-2):81-5. PubMed ID: 19477170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytical sensitivity of four commonly used hCG point of care devices.
    Kamer SM; Foley KF; Schmidt RL; Greene DN
    Clin Biochem; 2015 Apr; 48(6):448-52. PubMed ID: 25549977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative, wide-range, 5-minute point-of-care immunoassay for total human chorionic gonadotropin in whole blood.
    von Lode P; Rainaho J; Pettersson K
    Clin Chem; 2004 Jun; 50(6):1026-35. PubMed ID: 15073089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. False-negative results from point-of-care qualitative human chorionic gonadotropin (hCG) devices caused by excess hCGbeta core fragment vary with device lot number.
    Gronowski AM; Powers M; Stenman UH; Ashby L; Scott MG
    Clin Chem; 2009 Oct; 55(10):1885-6. PubMed ID: 19679628
    [No Abstract]   [Full Text] [Related]  

  • 18. Significance of pregnancy test false negative results due to elevated levels of β-core fragment hCG.
    Johnson S; Eapen S; Smith P; Warren G; Zinaman M
    J Immunoassay Immunochem; 2017; 38(4):449-455. PubMed ID: 28521601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limitations in qualitative point of care hCG tests for detecting early pregnancy.
    Greene DN; Schmidt RL; Kamer SM; Grenache DG; Hoke C; Lorey TS
    Clin Chim Acta; 2013 Jan; 415():317-21. PubMed ID: 23159297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of biotin interference with qualitative point-of-care hCG test devices.
    Williams GR; Cervinski MA; Nerenz RD
    Clin Biochem; 2018 Mar; 53():168-170. PubMed ID: 29395091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.